Clinical Trial Update: Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Eylea (aflibercept) for retinal pigment epithelium detachment secondary to age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration | Phase 4 | Status: COMPLETED